Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

Happy to see that the stock is up

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 4
Posts 607
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:18:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/5/2019 4:49:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/5/2019 4:42:36 PM
Oramed to Present at Three Upcoming Conferences PR Newswire (US) - 9/3/2019 8:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 5:28:25 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/6/2019 1:29:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 6:08:14 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/19/2019 12:12:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/18/2019 1:32:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/15/2019 7:03:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/10/2019 5:28:14 PM
Oramed to Present at World Diabetes Congress PR Newswire (US) - 7/10/2019 8:40:00 AM
Spideyboy   Wednesday, 07/05/17 02:43:47 PM
Re: None
Post # of 520 
Happy to see that the stock is up 9% on ORMP listing on the Tel Aviv stock exchange, but is there any particular benefit to this?

Would this not separate where people can buy shares and therefore reduce the volume of buying on either of the exchange compared to if everyone had to buy from the same Nasdaq stock?

Thank for any thoughts!
Spidey

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist